Research programme: anticancer antibodies - MorphoSys/Bayer
Latest Information Update: 01 Aug 2024
At a glance
- Originator Bayer; MorphoSys
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 May 2003 Preclinical trials in Cancer in USA (unspecified route)